| Project/Area Number |
15K10058
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
Abe Noriko 福島県立医科大学, 医学部, 講師 (30622336)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岡山 洋和 福島県立医科大学, 医学部, 助教 (20583397)
大竹 徹 福島県立医科大学, 医学部, 教授 (50363750)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 乳癌 / 糖鎖 |
|---|
| Outline of Final Research Achievements |
We previously reported that a carbohydrate determinant, MECA-79, is ectopically expressed in gastric cancer, and is associated with clinical outcomes. The present study attempted to focus on the clinical and functional implication of MECA-79 expression in breast cancer, using breast cancer specimens and breast cancer cell lines, mainly by immunohistochemistry and flow cytometry. Unlike gastric and colorectal cancer, only approximately 5% of breast cancer was considered positive for MECA-79 expression, although MECA-79 expression was occasionally observed in membrane and/or cytoplasm of breast cancer cells. MECA-79 expression was not significantly associated with clinicopatholgical parameters or clinical outcomes in breast cancer. Flow cytometric analysis revealed that cell surface MECA-79 expression was found in none of the 5 breast cancer cell lines. The role of ectopic expression of MECA-79 in breast cancer remains unclear, and further studies would be required.
|
